Countdown to Conference
Days
Hours
Min
Sec
 

PRESS

Cellular and Molecular Biology Programs

HomeProgramBrowse Programs and Exhibits by Topic ▶ Cellular and Molecular Biology Programs

Cellular/
Molecular Biology

The following programs are related to Cellular/Molecular Biology and are available on-demand through Friday, July 2.


Clinical and Scientific Sessions


The Clinical and Scientific Sessions and abstracts accepted for the program will be presented virtually through our online platform. Starting May 13, attendees can access on-demand content. The sessions listed with a date and time below will have a live component where you may pose questions to the speakers. All content will continue to be available on-demand through July 2.

Mini Symposia and Thematic Poster Sessions are abstract based sessions.

Browse all clinical and scientific sessions →

Session Title Session Type Join Us!
A004 PRECISION MEDICINE IN PEDIATRIC RESPIRATORY DISEASES: READY FOR PRIME TIME? Scientific Symposium 10 - 11 a.m. EDT, Sunday, May 16
A026 METABOLIC DYSREGULATION AND LUNG DISEASE: A COMMON THREAD BETWEEN CHILDREN AND ADULTS Scientific Symposium On-Demand
A029 VIRAL PNEUMONIA: NEW CONCEPTUAL APPROACHES TO THERAPY FROM BASIC AND CLINICAL RESEARCH Scientific Symposium On-Demand
B004 SEX AS A VITAL BIOLOGICAL VARIABLE IN LUNG DISEASE ACROSS THE LIFESPAN Scientific Symposium 8 - 9:30 a.m. EDT, Monday, May 17
B011 SEX CHANGES EVERYTHING: DIFFERENCES IN LUNG DISEASE BETWEEN MEN AND WOMEN Scientific Symposium 1:30 - 3 p.m. EDT, Monday, May 17
B023 LUNG CANCER RISK ASSESSMENT: CLINICAL MODELS X MOLECULAR BIOMARKERS Scientific Symposium On-Demand
C007 BEYOND VASCULAR RESIDENT CELLS: ONE NEEDS MANY PIECES TO PLAY AN ORCHESTRA Scientific Symposium 10 - 11:30 a.m. EDT, Tuesday, May 18
C010 TRANSFORMATIVE SCIENCE UPDATES IN TUBERCULOSIS THERAPEUTICS Scientific Symposium 1:30 - 3 p.m., EDT, Tuesday, May 18
Hot Topic sessions recommended by the International Conference Committee (ICC).

 

Industry Programs


Enhance your educational experience during ATS 2021 by listening to industry experts discuss the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine.

There are 24 programs from Sunday, May 16 – Wednesday, May 19 with a total of six programs each day – three programs from 12-1 p.m. ET and three programs from 5:30-6:30 p.m. ET.

Don’t miss programs that are live and only accessible during their program time! Some programs will be available on-demand shortly after their program time through the end of the virtual conference, July 2.

Browse all industry programs →


Clinical Perspectives and Evidence for Use of Single Inhaler Triple Therapy for Adult Patients With COPD or Asthma


Sponsored by GlaxoSmithKline
Live
Sunday, May 16, 12 - 1 p.m. EDT | Open to U.S. attendees only
Topic: Asthma/COPD

Add to My Calendar

Join an expert panel to explore clinical evidence supporting the use of single inhaler triple therapy for the maintenance treatment of adult patients with COPD or asthma. Throughout this program, panelists will draw on their experience and clinical data to provide insights into triple therapy use. In addition to the panel discussion, this program will conclude with an opportunity for live Q&A to address audience questions.

Speakers:

  • Nicole Chase, MD, St. Paul Allergy & Asthma Clinic
  • Sandeep Bansal, MD, FCCP, FACP, The Lung Center & Intensive Care at Penn Highlands Healthcare



Comparative Effectiveness of ERAs on Mortality in Patients with PAH in a US Medicare Population: A Retrospective Database Analysis

Sponsored by Janssen, a Pharmaceutical Company of Johnson & Johnson
Live
Sunday, May 16, 12 - 12:30 p.m. EDT | Open to all attendees
Topic: Pulmonary Arterial Hypertension (PAH)

Add to My Calendar

Pulmonary arterial hypertension (PAH) is a chronic, progressive disease characterized by restricted blood flow through the pulmonary arterial vasculature, leading to increased pulmonary vascular resistance and, ultimately, right heart failure. This virtual Industry Program will review findings from a retrospective database analysis that details comparative effectiveness of endothelin receptor antagonists (ERAs) on mortality in patients with PAH in a US Medicare population. This program will be offered at two times: 12:00 p.m. – 12:30 p.m. EDT, Sunday, May 16, 2021 5:30 p.m. – 6:00 p.m. EDT, Monday, May 17, 2021 This is a non-CME educational program sponsored by Janssen, a Pharmaceutical Company of Johnson & Johnson.

Speaker:

  • Raymond L. Benza, MD, Professor and Director, Div. of Cardiovascular Medicine, Bob and Corrine Frick Endowed Chair in Heart Failure, The Ohio State University Wexner Medical Center



Interactive Exchange™ – Swimming Upstream in Severe Asthma: New Pathways to Patient Management


This non-CME educational program is jointly sponsored by Integritas Communications and Global Education Group and is supported by an independent educational grant from AstraZeneca.
Live and available on-demand
Sunday, May 16, 12 - 1 p.m. EDT | Open to all attendees
Topic: Asthma

Add to My Calendar

This virtual live Interactive Exchange™ severe asthma program will provide a blended educational format that promotes opportunities for various interactions and dialogue among presenting faculty and participants. The program will begin with an introductory video animation that imparts foundational information─including key upstream inflammatory pathways, the role of the epithelium in asthma development, mechanisms underlying common phenotypes, and the rationale for targeted biologic therapies─for the program’s interactive discussions. Expert faculty will focus on key topics, such as recent clinical trial evidence for emerging pharmacotherapies that target type 2 (T2)–low disease, potential changes to evidence-based treatment algorithms, and strategies for effectively communicating biologic treatment options with patients. This multimedia experience will deliver optimized participant engagement while ensuring the sharing of experiences surrounding challenging clinical topics in today’s severe asthma landscape.

Speakers:

  • Reynold A. Panettieri, Jr., MD, Professor of Medicine, Robert Wood Johnson Medical School Vice Chancellor, Clinical & Translational Science Director, Rutgers Institute for Translational Medicine & Science Emeritus Professor of Medicine, University of Pennsylvania, Child Health Institute of New Jersey
    Rutgers, The State University of New Jersey
  • Jonathan Corren, MD, Associate Clinical Professor of Medicine and Pediatrics Medical Director, Jonathan Corren M.D. and Associates, David Geffen School of Medicine, University of California, Los Angeles
  • Monica Kraft, MD, Professor, Medicine Chair, Department of Medicine The Robert and Irene Flinn Endowed Chair in Medicine Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center, University of Arizona (UA) College of Medicine – Tucson



Clinical and Real-World Evidence for a Biologic in the Management of Severe Eosinophilic Asthma


Sponsored by GlaxoSmithKline
Live
Sunday, May 16, 5:30 - 6:30 p.m. EDT | Open to U.S attendees only
Topic: Eosinophilic Asthma (EOS)

Add to My Calendar

The program will review the efficacy and safety of a biologic in patients with severe eosinophilic asthma, highlighting results from a real-world study and a long-term study. The discussion will also include a review of patient cases and clinical approaches to patient identification, assessment, and management. This event will last approximately 45 minutes and conclude with an optional Q&A.

Speakers:

  • Geoffrey Chupp, MD, Director, Yale Center for Asthma and Airways Disease, Yale University
  • Diego J. Maselli Caceres, MD, Medical Director, Severe Asthma Program, University of Texas Health at San Antonio



Exposing a Hidden Majority in COPD: Real-World Insights on Outcomes and Dual Bronchodilation


Sponsored by Boehringer Ingelheim
On-demand
Sunday, May 16, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: COPD

Add to My Calendar

During this event, our experts will review:

  • How has the pandemic posed challenges for COPD management and in what ways have clinicians adapted?
  • Are the appropriate patients getting dual bronchodilation and how can patient phenotypes inform inhaler choice?
  • What can real-world evidence tell us about health outcomes with dual bronchodilation and how does compliance with GOLD treatment guidelines impact health outcomes?

Speakers:

  • Nicola Hanania, MD, MS, Associate Professor of Medicine in the Section of Pulmonary and Critical Care Medicine and Director of the Asthma and COPD Clinical Research Center, Baylor College of Medicine
  • Sanjay Sethi, MD, Professor of Medicine, Chief of the Pulmonary/Critical Care/Sleep Medicine Division, Assistant Vice President for Health Services, Director of the Clinical Research Office and Deputy Director of the UB Clinical and Translational Science Institute, University of Buffalo, SUNY



PRECISION: Using Evidence-based Tools to Advance the Identification and Management of Uncontrolled Asthma


Sponsored by AstraZeneca
Live and available on-demand
Sunday, May 16, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: Asthma

Add to My Calendar

This program aims to help health care providers:

  • Recognize the importance of past, present, and future burden associated with uncontrolled asthma in the United States
  • Gain awareness of interventions designed to improve the diagnosis and management of uncontrolled asthma
  • Understand how the PRECISION initiative has united a network of diverse scientific and clinical leaders and local health care professionals to help address the unmet need associated with uncontrolled asthma
  • Learn about PRECISION tools designed for all clinicians to help with identifying and assessing uncontrolled asthma and accelerating the patient journey toward precision medicine in practice

Speakers:

  • Shyam Subramanian, MD, FCCP, Section Chief, Specialty Clinics, Division Chief, Pulmonary/Critical Care/Sleep, Sutter Gould Medical Foundation, Tracy, CA



A Breath of Fresh Air in Pediatric Asthma


This non-CME educational program is sponsored by Integritas Communications and is supported by an independent educational grant from Regeneron Pharmaceuticals and Sanofi Genzyme.
Live and available on-demand
Monday, May 17, 12 - 1 p.m. EDT | Open to all attendees
Topic: Asthma

Add to My Calendar

During this 1-hour Engaging the Patient™ program, two asthma specialists will review the consequences and disparities of severe asthma within the pediatric population and share their interpretive insights on its characteristics and underlying pathophysiology as well as the rationale for targeted biologic therapies. Additionally, the latest clinical trial evidence for the use of newer biologic therapies within this pediatric population will be presented along with their positioning within recent published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision making will support the translation of this information to practice. Lastly, an intimate view of the parents’ perspective will be provided via prerecorded video, highlighting the immense burden of disease and the impact asthma has on patients and their families. Following participation, attendees will be motivated and better prepared to implement timely and effective treatment plans for the management of their young patients with severe asthma.

Speakers:

  • Mario Castro, MD, MPH, Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research; Director, Frontiers: University of Kansas Clinical and Translational Science Institute; Director, Rainbow Clinical Trials Science Unit, University of Kansas Medical Center
  • Wanda Phipatanakul, MD, MS, Professor of Pediatrics; Director, Clinical Research Center, Harvard Medical School; Boston Children's Hospital



Targeting Eosinophils: A Potent Contributor to Severe Asthma


Sponsored by AstraZeneca
On-demand
Monday, May 17, 12 - 1 p.m. EDT | Open to all attendees
Topic: Asthma

Add to My Calendar

It’s time to rethink patient goals in severe asthma. Please join us to view a pre-recorded program to learn about a targeted biologic treatment option that targets a key contributor of severe uncontrolled asthma. Listen to a national expert to explore this treatment option’s clinical efficacy, mechanism of action, safety profile data, and hypothetical patient cases.

Speakers:

  • Michael Wechsler, MD, MMSc, Pulmonologist, Director, Cohen Family Asthma Institute, Director, Asthma Program, Professor of Medicine, National Jewish Health, Denver, CO



Comparative Effectiveness of ERAs on Mortality in Patients with PAH in a US Medicare Population: A Retrospective Database Analysis

Sponsored by Janssen, a Pharmaceutical Company of Johnson & Johnson
Live
Monday, May 17, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: Pulmonary Arterial Hypertension (PAH)

Add to My Calendar

Pulmonary arterial hypertension (PAH) is a chronic, progressive disease characterized by restricted blood flow through the pulmonary arterial vasculature, leading to increased pulmonary vascular resistance and, ultimately, right heart failure. This virtual Industry Program will review findings from a retrospective database analysis that details comparative effectiveness of endothelin receptor antagonists (ERAs) on mortality in patients with PAH in a US Medicare population. This program will be offered at two times: 12:00 p.m. – 12:30 p.m. EDT, Sunday, May 16, 2021 5:30 p.m. – 6:00 p.m. EDT, Monday, May 17, 2021 This is a non-CME educational program sponsored by Janssen, a Pharmaceutical Company of Johnson & Johnson.

Speaker:

  • Raymond L. Benza, MD, Professor and Director, Div. of Cardiovascular Medicine, Bob and Corrine Frick Endowed Chair in Heart Failure, The Ohio State University Wexner Medical Center



TSLP in Asthma: Examining the Evidence


Sponsored by Amgen / AstraZeneca
On-demand
Monday, May 17, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: Asthma

Add to My Calendar

There’s a new way to think about asthma and it starts at the top of the inflammatory cascade. Join us as two experts explore the role of a key epithelial cytokine, thymic stromal lymphopoietin (TSLP), in driving multiple downstream inflammatory pathways.

Speakers:

  • Mario Castro, MD, MPH, Pulmonologist Chief, Pulmonary, Critical Care and Sleep Medicine Vice Chair for Clinical and Translational Research Director, Frontiers: University of Kansas Clinical and Translational Science Institute Director, Rainbow Clinical Trials Science Unit, University of Kansas School of Medicine



Exploring Type 2 Inflammation in Nasal Polyps and Beyond


Sponsored by Novartis Pharmaceuticals Corporation
On-demand
Tuesday, May 18, 12 - 12:30 p.m. EDT | Open to U.S. attendees only
Topic: Airway Comorbidities

Add to My Calendar

A disease state overview of nasal polyps and type 2 inflammation

Speakers:

  • Monica Kraft, MD, The Robert and Irene Flinn Endowed Chair in Medicine, The University of Arizona College of Medicine



Serotonin Pathobiology in Pulmonary Arterial Hypertension and Phase 2b Investigation of the Novel Therapy Rodatristat Ethyl (RE) in WHO Group 1 PAH


Sponsored by Altavant Sciences
On-demand
Tuesday, May 18, 5:30 - 6 p.m. EDT | Open to all attendees
Topic: Pulmonary Arterial Hypertension

Add to My Calendar

This program will include an expert overview of the role serotonin plays in the pathogenesis of PAH, present the mode of action of rodatristat ethyl; a novel inhibitor of peripheral serotonin via targeting of tryptophan hydroxylase 1, and provide an overview of the phase 2b clinical program, ELEVATE 2

Speakers:

  • Bill Symonds, PharmD, Chief Executive Officer, Altavant Sciences
  • Marc Humbert, MD, PhD, Professor, Respiratory Medicine, Université Paris-Saclay
  • Stephen Wring, PhD, Vice President, Research and Development, Altavant Sciences
  • Howard M Lazarus, MD, Chief Medical Officer, Altavant Sciences



Tips and Tricks for Bronchoscopic Lung Volume Reduction for Advanced Emphysema


Sponsored by Temple Lung Center
Live and available on-demand
Tuesday, May 18,
5:30 - 6 p.m. EDT | Open to all attendees
Topic: COPD

Add to My Calendar

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Despite optimal pharmacological treatment, many patients with chronic obstructive pulmonary disease remain very disabled. Bronchoscopic lung volume reduction, which involves the insertion of valves into the airways with the intension of improving operating lung volume, could be a valuable treatment option for some patients with advanced emphysema. In this program, participants will learn procedural tips and tricks regarding valve placement from internationally renowned EBV expert Gerard Criner, MD.

Speakers:

  • Gerard J. Criner, MD FACP, FACCP, Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Temple University Health System
  • Nathaniel Marchetti, DO, Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Temple University Health System



Targeting Systemic and Localized Type 2 Inflammation in Asthma


Sponsored by Regeneron and Sanofi Genzyme
Live
Wednesday, May 19, 12 - 1 p.m. EDT | Open to all attendees
Topic: Asthma

Add to My Calendar

Learn the importance of identifying systemic and localized Type 2 inflammation in your patients with moderate-to-severe, uncontrolled asthma. In this virtual event, an expert will apply these concepts into their case-based review of a patient with asthma.

Speakers:

  • Cedric "Jamie" Rutland, MD, CEO and Medical Director, Rutland Medical Group



IPF Disease Challenge


This non-CME educational program is sponsored by the France Foundation and supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Live and available on-demand
Wednesday, May 19, 5:30 - 6:30 p.m. EDT | Open to all attendees
Topic: IPF

Add to My Calendar

Are you up for the IPF Disease Challenge? Game on!
Unwind after a long day with a Kahoot!

This is NOT an old-school didactic lecture! Discover better ways to manage your patients with IPF while engaging in some “friendly competition.” Gaming elements will answer questions such as:

  • How do I integrate new IPF treatment info into practice?
  • When and why would I start antifibrotic therapy?
  • Should I stop or switch treatment?
  • How do I emphasize to patients that treatment adherence impacts disease progression?

Hosted by Kevin Flaherty, MD, from the University of Michigan and Lisa H. Lancaster, MD, from Vanderbilt University.

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Speakers:

  • Lisa H. Lancaster, MD, Medical Director Interstitial Lung Disease Program, Professor of Medicine, Vanderbilt University
  • Kevin Robert Flaherty, MD, Director of the Michigan Medicine Interstitial Lung Disease Program, Professor of Medicine, University of Michigan



Two Approaches to COPD: Focus on the lungs or look beyond?

Sponsored by AstraZeneca
Live and available on-demand
Wednesday, May 19, 5:30 - 6 p.m. EDT | Open to U.S. attendees only
Topic: COPD

Add to My Calendar

To help address the ongoing burden of COPD mortality, two speakers will discuss how views on COPD are changing and if we should still approach COPD as a disease only affecting the lungs. You decide.

Speakers:

  • MeiLan Han, MD, MS, Professor of Medicine, Division of Pulmonary and Critical Care, University of Michigan
  • Fernando Martinez, MD, MS, Chief of the Pulmonary and Critical Care Medicine Division, Weill Cornell Medicine

Exhibitors


The ATS 2021 Virtual Exhibits in the Industry Solutions Center offer the latest innovations and newest advances in pulmonary, critical care and sleep medicine. Stop by these exhibitors to learn more about the latest in Cellular/Molecular Biology:

  • Asian Pacific Society of Respirology (APSR)
  • Biodesix, Inc.
  • BioFire Diagnostics
  • BRUKER
  • Cystic Fibrosis Research Institute
  • Data Sciences Internatonal (DSI)
  • Fidelta Ltd.
  • FUJIFILM Medical Systems U.S.A., Inc.
  • Hermansky-Pudlak Syndrome
  • Med Learning Group
  • Sociedad Mexicana De Neumología Y Cirugía De Tórax
  • Vertex Pharmaceuticals, Inc.


You can also access:


  • Abstract Presentations
  • Networking Opportunities
  • MOC points and CME Credit
  • Q & A and Chat With Speakers and Authors
  • San Diego Sleuth Challenge
  • Wellness Activities